The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.
At the moment of publication, the compound presented is solely approved for use in the US by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The compound is still being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
European Association for the Study of Diabetes September 27 – October 1, 2021
Presentations of the Scientific Symposium at the EASD 57th Annual Meeting 2021
Thank you for your interest! See below to watch the session recording of the EASD symposium video.
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
Finerenone
Friday 1 October, 2021 | 11:15 - 12:45 CEST | On Demand
Finerenone: a new approach to kidney protection in patients with type 2 diabetes
Session type: Scientific Symposium Faculty: Ralph DeFronzo, George Bakris, Luis Ruilope, Janet McGill, Andreas Birkenfeld, Rajiv Agarwal, Per-Henrik Groop
Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.
View Video
More Information
For more information regarding Finerenone visit us by clicking the link below
The compound presented is approved for use by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D) but is investigational or being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.
Date accessed: 1 September, 2021
MA-M_FIN-ALL-0525-1